Phase 2 study of 5'-DFUR for bladder and prostatic cancer

H. Ohmori, Y. Matsumura, J. Ochi, K. Kobashi, N. Akebi, T. Saika, K. Nanba, T. Tanahashi, T. Josen, Y. Nasu, M. Saegusa, Y. Ozaki, M. Hara, T. Asahi, N. Ike, T. Tsushima, N. Mitsuhata, T. Akagi, T. Kaeda

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)

    Abstract

    Phase 2 study of 5'-DFUR in bladder and prostatic cancer was conducted at 15 collaborative institutions including Okayama University. 5'-DFUR was orally administered to patients at a daily dose of 800-1200 mg for more than 4 weeks. Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated. The response rate for bladder cancer was 31.7% (CFR, 1 case: PR, 12 cases), against no response with prostatic cancer. Moreover, the concentration of 5-FU in bladder tumors was confirmed to be high. Adverse reactions such as diarrhea, anorexia, and nausea were observed. Thus, 5'-DFUR seems to be useful for the treatment of bladder cancer.

    Original languageEnglish
    Pages (from-to)2307-2314
    Number of pages8
    JournalJapanese Journal of Cancer and Chemotherapy
    Volume18
    Issue number13
    Publication statusPublished - Jan 1 1991

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Phase 2 study of 5'-DFUR for bladder and prostatic cancer'. Together they form a unique fingerprint.

    Cite this